Literature DB >> 33781760

Expanding access to medication abortion through pharmacy dispensing of mifepristone: Primary care perspectives from Illinois.

Kayla N Rasmussen1, Elizabeth Janiak2, Alischer A Cottrill2, Debra B Stulberg3.   

Abstract

OBJECTIVE: Medication abortion is safe and effective, yet access is limited by a strict Risk Evaluation and Mitigation Strategy (REMS) that prohibits pharmacy dispensing of mifepristone. Given the ability of primary care providers (PCPs) to expand medication abortion access, we assessed PCP perspectives on how lifting the mifepristone REMS would affect the provision of medication abortion in primary care. STUDY
DESIGN: We conducted a qualitative study of PCPs and administrators in Illinois with experience or interest in providing medication abortion care at their practice. The final sample (N=19) consisted of seven family medicine physicians, three nurse practitioners, four certified nurse midwives, and five administrators. We queried participants on how removing the REMS to allow pharmacy dispensing of mifepristone would affect their ability to provide medication abortion. We conducted interviews via telephone and used ATLAS.ti to manage our transcripts; we analyzed these data for major themes regarding pharmacy dispensing.
RESULTS: Primary care providers expressed support for pharmacy dispensing due to its ability to help normalize medication abortion, reduce implementation barriers in primary care, and expand abortion access. Further challenges to address if the REMS restrictions are lifted include federal funding restrictions on abortion, concerns about unsupervised mifepristone use, and pharmacy cooperation.
CONCLUSION: Removing the mifepristone REMS to allow pharmacy dispensing could help normalize medication abortion care, facilitate provision in primary care, and address disparities in abortion access. IMPLICATIONS: Our findings illuminate novel benefits of removing the mifepristone REMS and highlight methods to promote successful implementation of pharmacy dispensing. Combined with prior literature, these results support prompt reevaluation and removal of the REMS to align medication abortion care with evidence-based practices.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medication abortion; Mifepristone; Pharmacy dispensing; Primary care

Year:  2021        PMID: 33781760     DOI: 10.1016/j.contraception.2021.03.022

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

Review 1.  The impact of provider restrictions on abortion-related outcomes: a synthesis of legal and health evidence.

Authors:  Fiona de Londras; Amanda Cleeve; Maria I Rodriguez; Alana Farrell; Magdalena Furgalska; Antonella F Lavelanet
Journal:  Reprod Health       Date:  2022-04-18       Impact factor: 3.355

2.  Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.

Authors:  Enav Z Zusman; Sarah Munro; Wendy V Norman; Judith A Soon
Journal:  BMJ Open       Date:  2022-10-07       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.